Myriad Genetics Screens & Tests

BRACAnalysis CDx product signature

BRACAnalysis CDx® is an FDA-approved test used to identify patients with germline BRCA1/2 mutations who may be eligible for certain targeted therapies.

  • For patients with breast, ovarian, pancreatic or prostate cancer
  • FDA approved, accurate germline BRCA1/2 testing to identify eligibility for targeted therapies
  • No family history is required to meet genetic testing guidelines
EndoPredict product signature
For patients with ER+, HER2-, node-negative or node-positive breast cancer, EndoPredict® provides three individualized results to use to help determine the right breast cancer treatment decisions.
FOLR1/FRA product signature

IHC Test to identify patients with ovarian cancer who may qualify for treatment with mirvetuximab

Foresight® Carrier Screen product signature

Foresight® Carrier Screen detects a couple’s risk of passing down serious, inheritable health conditions to their child to guide informed planning and preparation.

  • Identify the 1 in 22 couples at risk for pregnancies with serious, prevalent, or clinically-actionable inherited conditions
  • 99% detection rate across ethnicities for the vast majority of the 176 genes on our panel2
GeneSight® Mental Health Medication Test product signature

The GeneSight® Psychotropic test analyzes how a patient’s genes may affect their outcomes with medications commonly prescribed to treat depression, anxiety, ADHD and other mental health conditions.

  • Delivers genetic insights that can help inform your mental health treatment plans
  • Access to test significantly improved remission and response rates compared to treatment as usual3
  • Ordered by tens of thousands of clinicians for 2MM+ patients
MyChoice® CDx product signature

For patients with ovarian cancer, MyChoice® CDx examines an ovarian cancer tumor’s HRD status to help determine whether a patient may be a candidate for PARP inhibitor therapy.

MyRisk™ product signature

MyRisk® Hereditary Cancer Test is a multi-gene panel that helps to determine a patient’s risk by evaluating a number of hereditary cancer syndromes, with focus on 11 primary cancer sites.

  • All-in-one personalized cancer risk assessment
  • Evaluates 48 genes associated with 11 different hereditary cancers
  • RiskScore® predicts a patient’s 5-year and lifetime risk of developing breast cancer
Precise™ Tumor product signature
Precise Tumor is a pan-cancer, comprehensive laboratory test that uses state-of-the-art, next-generation sequencing to discover and target important variants within tumors.
Prequel®Prenatal Screen product signature

Designed for everyone regardless of ancestry and BMI or ability to pay, the Prequel® Prenatal Screen can determine if a pregnancy is at an increased risk for a wide variety of chromosomal conditions as early as 10 weeks.

  • The only non-invasive prenatal screening (NIPS) that uses AMPLIFY™ technology
  • 99.9% result delivery on the first draw at 10 weeks1
  • Accessible and reliable for everybody, regardless of BMI, ancestry, or ability to pay
Prolaris® product signature

Prolaris® is a molecular diagnostic test that helps determine the aggressiveness of a prostate cancer tumor to guide the best treatment decisions for prostate cancer patients.

SneakPeek® product signature
For expectant parents, SneakPeek is a test that reveals the predicted fetal sex as early as six weeks into pregnancy with >99% accuracy.

Illuminating the path to better health through genetic insights

Our tests and screens reveal information to guide patients and providers to better health and well-being. Whether you’re searching for answers related to cancer risk, cancer treatment, prenatal care or mental health, Myriad screens and tests can help.